TOKYO, Aug 13 (Reuters) - Japan's Astellas Pharma said on Thursday a U.S. court has rejected its request for an injunction to prevent the Food and Drug Administration from approving generic products to its top-selling Prograf transplant drug.
Astellas, Japan's No.2 drugmaker, filed a complaint against the FDA, after the U.S. drug regulators knocked back its request for higher hurdles for generic rivals to Prograf.
Swiss drugmaker Novartis launched the first generic version of Prograf on Tuesday, sending Astellas shares 8 percent lower over the last two days.
The stock was up 0.8 percent at 3,600 yen in early trade on Thursday.
Astellas said in a statement it is evaluating its next course of action. (Reporting by Yumiko Nishitani; Editing by Edwina Gibbs)